| Literature DB >> 28955905 |
Srijit Das1, Nitai Pada Bhattacharyya1,2.
Abstract
Heat shock response is an adaptive mechanism of cells characterized by rapid synthesis of a class of proteins popularly known as heat shock proteins (HSPs) by heat-induced activation of Heat Shock Factor 1 (HSF1). In course of our earlier study to show that HSF1 regulates transcription of HYPK (Huntingtin Yeast two-hybrid protein K), a chaperone-like protein, we observed presence of few other genes within 10 kb of HYPK promoter. In an attempt to understand whether adjacent genes of HYPK are co-regulated, we identified that SERF2 (small EDRK-rich factor 2), an upstream neighboring gene of HYPK, is also regulated by heat stress and HSF1. We also showed that SERF2 promoter can be trans-activated by HSF1 due to the presence of functional heat shock element (HSE). Strikingly, HYPK is linked with SERF2 through a Conjoined Gene (CG) albeit the respective proteins have opposite effect on mutant Huntingtin aggregates and subsequent toxicity. Our study provides the first report on regulation of SERF2 expression and thereby depicts a paradigm where two parent genes of a CG are regulated by a common transcription factor despite the fact that they code for proteins having opposite cellular function in a given context.Entities:
Keywords: CG, Conjoined Gene; Conjoined Gene; HS, heat shock; HSE, Heat Shock Element; HSF1, Heat Shock Factor 1; HYPK, Huntingtin Yeast-Two-Hybrid Protein K; Heat Shock Factor 1; Huntingtin Yeast-two-hybrid protein K; SERF2, small EDRK-Rich Factor 2; small EDRK-rich factor 2
Year: 2016 PMID: 28955905 PMCID: PMC5613254 DOI: 10.1016/j.bbrep.2016.04.003
Source DB: PubMed Journal: Biochem Biophys Rep ISSN: 2405-5808
Fig. 1Hyperthermia increases SERF2 expression in HeLa cells. Bar graph representative of three independent experiments (n=3) for qRT-PCR of (A)SERF2, (B)SERINC4 and (C)hsp70 expression in HeLa cells undergoing no heat shock (HS) treatment (control) or subjected to HS treatment at 42 °C for 60 min followed by recovery at 37 °C for 0, 2, 4 and 6 h. Expression of β-actin was taken as endogenous control. (D) Western Blot analysis for the expression of SERF2 in three independent experiments (n=3) in HeLa cells in absence or presence of HS treatment. β-actin was used as loading control. Error bars indicate ± SD. The statistical significance level between various experimental pairs is indicated (*,p<0.05;**,p<0.01;***,p<0.001).
Fig. 2Functional validation of the HSE present in SERF2 promoter. A. Luciferase reporter assay (n=3) of different reporter constructs (SERF2_ups, SERF2_ups_ΔHSE and Hsp70_ups) in HeLa cells undergoing no HS treatment (control) and standard HS treatment. B. Luciferase reporter assay (n=3) of three reporter constructs mentioned in A in HeLa cells transiently transfected with empty pcDNA vector (control) and HSF1-pcDNA in presence of standard HS treatment. C. Chromatin immunoprecipitation showing in vivo interaction of HSF1 and RNA polymerase II with the SERF2 promoter and acetylation of histone H4 (AcH4) at the same site in HeLa cells in absence or presence of HS treatment. Input and immunoprecipitated DNA was PCR-amplified using primers flanking the HSF1-binding site present in SERF2 promoter. Lane IN: PCR amplification was carried out using DNA isolated from HeLa cells subjected to no HS or HS treatment. Lane +Ab: PCR amplification was carried out using chromatin immunoprecipitated by anti-HSF1, anti-RNA polymerase II and anti-AcH4 (acetylated histone H4) antibodies. Lane IgG: PCR amplification was carried out using chromatin immunoprecipitated by IgG alone. Lane –Ve: PCR amplification was carried out without adding any template DNA. D. Quantitative analysis of ChIP assay. DNA from different samples described in C was amplified by qRT-PCR using mouse SERF2 promoter-specific primers. The immunoprecipitated DNA was normalized by respective input DNA in each sample and fold enrichment was calculated by considering the normalized immunoprecipitated DNA in unstressed cells (control) as 1. Error bars indicate ± SD. The statistical significance level between various experimental pairs is indicated (*,p<0.05;**,p<0.01;***,p<0.001).
Fig. 3In vivo interaction of HSF1 with recombinant SERF2 promoter. Transient chromatin immunoprecipitation assay showing in vivo interaction of HSF1 with SERF2 and hsp70 promoter cloned in pGL3 vector. HeLa cells were transiently transfected with SERF2_ups, SERF2_ups_ΔHSE and Hsp70_ups constructs and transfected cells were either left untreated (no HS treatment) or subjected to HS treatment. Immunoprecipitation was carried out using anti-HSF1 antibody and precipitated DNA was PCR-amplified using primers described in Methods section. The lane markings are as described in Fig. 2C.
Fig. 4Effect of HSF1 on SERF2 expression. A. Average (n=3) expression of SERF2 in HeLa cells transiently expressing empty pSUPER vector (control), HSF1-siRNA containing pSUPER vector and scrambled RNA containing pSUPER vector. B. Average (n=3) expression of SERF2 in HeLa cells expressing different pSUPER constructs mentioned in A in absence (control) or presence of HS treatment. C. Bar graph showing mean (n=3) SERF2 expression in DMSO-treated (control) and 5 μM 17-AAG treated HeLa cells. Expression of β-actin was used as endogenous control in all experiments. Error bars indicate ± SD. The statistical significance level between various experimental pairs is indicated (*,p<0.05;**,p<0.01;***,p<0.001).